Unsaturated fatty acids repress the expression of ATP-binding cassette transporter A1 in HepG2 and FHs 74 Int cells

Nutrition Research

Volumn 31, Issue 4, 2011, Pages 278-285

  Ku, Chai Siah ^a   Rasmussen, Heather E ^b   Park, Youngki ^a   Jesch, Elliot D ^b   Lee, Jiyoung ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

ABCA1; Fatty acids; FHs 74 Int cells; HepG2 cells

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PALMITIC ACID; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; UNSATURATED FATTY ACID;

ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME REPRESSION; FATTY ACID ANALYSIS; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROCESSING;

ACETOPHENONES; ATP-BINDING CASSETTE TRANSPORTERS; BENZOPYRANS; BLOTTING, WESTERN; FATTY ACIDS, UNSATURATED; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INTESTINE, SMALL; LIPOPROTEINS, HDL; LIVER; PROTEIN KINASE C-DELTA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 79955432055     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2011.03.007     Document Type: Article

References (67)

1. Oram J.F. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003, 23:720-727.
2. Rogler G., Trumbach B., Klima B., Lackner K.J., Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol 1995, 15:683-690.
3. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest 1995, 96:78-87.
4. Oram J.F. Tangier disease and ABCA1. Biochim Biophys Acta 2000, 1529:321-330.
5. Francone O.L., Subbaiah P.V., van Tol A., Royer L., Haghpassand M. Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1. Biochemistry (Mosc) 2003, 42:8569-8578.
6. McNeish J., Aiello R.J., Guyot D., Turi T., Gabel C., Aldinger C., et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 2000, 97:4245-4250.
7. Brunham L.R., Kruit J.K., Iqbal J., Fievet C., Timmins J.M., Pape T.D., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006, 116:1052-1062.
8. Timmins J.M., Lee J.Y., Boudyguina E., Kluckman K.D., Brunham L.R., Mulya A., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005, 115:1333-1342.
9. Naik S.U., Wang X., Da Silva J.S., Jaye M., Macphee C.H., Reilly M.P., et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006, 113:90-97.
10. Mauerer R., Ebert S., Langmann T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATP-binding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp Mol Med 2009, 41:126-132.
11. Uehara Y., Engel T., Li Z., Goepfert C., Rust S., Zhou X., et al. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 2002, 51:2922-2928.
12. Uehara Y., Miura S., von Eckardstein A., Abe S., Fujii A., Matsuo Y., et al. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 2007, 191:11-21.
13. Wang Y., Kurdi-Haidar B., Oram J.F. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004, 45:972-980.
14. Wang Y., Oram J.F. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 2002, 277:5692-5697.
15. Wang Y., Oram J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J Biol Chem 2005, 280:35896-35903.
16. Wang Y., Oram J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 2007, 48:1062-1068.
17. Murthy S., Born E., Mathur S.N., Field F.J. Liver-X-receptor-mediated increase in ATP-binding cassette transporter A1 expression is attenuated by fatty acids in CaCo-2 cells: effect on cholesterol efflux to high-density lipoprotein. Biochem J 2004, 377:545-552.
18. Barter P.J., Rye K.A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121:1-12.
19. McGill H.C., McMahan C.A., Malcom G.T., Oalmann M.C., Strong J.P. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 1995, 15:431-440.
20. Welborn T.A., Knuiman M., McCann V., Stanton K., Constable I.J. Clinical macrovascular disease in Caucasoid diabetic subjects: logistic regression analysis of risk variables. Diabetologia 1984, 27:568-573.
21. Reckless J.P., Betteridge D.J., Wu P., Payne B., Galton D.J. High-density and low-density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med J 1978, 1:883-886.
22. Briones E.R., Mao S.J., Palumbo P.J., O'Fallon W.M., Chenoweth W., Kottke B.A. Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics. Metabolism 1984, 33:42-49.
23. Biesbroeck R.C., Albers J.J., Wahl P.W., Weinberg C.R., Bassett M.L., Bierman E.L. Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 1982, 31:126-131.
24. Sprafka J.M., Xue S., Bushhouse S.A., French L.R., Martinez A.M., Goetz F.C. Cardiovascular disease risk factors and glucose tolerance. The Wadena City Health Study. Ann Epidemiol 1992, 2:647-656.
25. Garcia M.J., McNamara P.M., Gordon T., Kannel W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105-111.
26. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
27. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
28. Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968, 9:155-167.
29. Pieters M.N., Schouten D., Van Berkel T.J. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994, 1225:125-134.
30. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36:211-228.
31. Boden G., Chen X., Ruiz J., White J.V., Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994, 93:2438-2446.
32. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992, 258:766-770.
33. Reaven G.M., Hollenbeck C., Jeng C.Y., Wu M.S., Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988, 37:1020-1024.
34. Perseghin G., Ghosh S., Gerow K., Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997, 46:1001-1009.
35. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
36. Dentin R., Benhamed F., Hainault I., Fauveau V., Foufelle F., Dyck J.R., et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006, 55:2159-2170.
37. Petersen K.F., Shulman G.I. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002, 90:11G-18G.
38. Ravussin E., Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002, 967:363-378.
39. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46:3-10.
40. Kelley D.E., Simoneau J.A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:2349-2356.
41. Kraegen E.W., Clark P.W., Jenkins A.B., Daley E.A., Chisholm D.J., Storlien L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991, 40:1397-1403.
42. Westerbacka J., Corner A., Tiikkainen M., Tamminen M., Vehkavaara S., Hakkinen A.M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004, 47:1360-1369.
43. Zhang Y.L., Hernandez-Ono A., Ko C., Yasunaga K., Huang L.S., Ginsberg H.N. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem 2004, 279:19362-19374.
44. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
45. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008, 118:829-838.
46. Savage D.B., Petersen K.F., Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007, 87:507-520.
47. Coleman S.L.P., Park Y.K., Lee J.Y. Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr 2011, Epub ahead of print Nov 3, 2010.
48. Park Y.K., Rasmussen H.E., Ehler S.J., Blobaum K.R., Lu F., Schlegel V.L., et al. Repression of proinflammatory gene expression by lipid extract of Nostoc commune var sphaeroides Kutzing, a blue-green alga, via inhibition of nuclear factor-kappa B in RAW 264.7 macrophages. Nutr Res 2008, 28:83-92.
49. Rasmussen H.E., Blobaum K.R., Park Y.K., Ehlers S.J., Lu F., Lee J.Y. Lipid extract of Nostoc commune var. sphaeroides Kutzing, a blue-green alga, inhibits the activation of sterol regulatory element binding proteins in HepG2 cells. J Nutr 2008, 138:476-481.
50. Arakawa R., Hayashi M., Remaley A.T., Brewer B.H., Yamauchi Y., Yokoyama S. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J Biol Chem 2004, 279:6217-6220.
51. Arakawa R., Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem 2002, 277:22426-22429.
52. Wendt T., Bucciarelli L., Qu W., Lu Y., Yan S.F., Stern D.M., et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002, 4:228-237.
53. Howard B.V., Rodriguez B.L., Bennett P.H., Harris M.I., Hamman R., Kuller L.H., et al. Diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002, 105:e132-e137.
54. Grundy S.M., Howard B., Smith S., Eckel R., Redberg R., Bonow R.O., et al. Diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231-2239.
55. Mulya A., Lee J.Y., Gebre A.K., Thomas M.J., Colvin P.L., Parks J.S. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 2007, 27:1828-1836.
56. Mulya A., Lee J.Y., Gebre A.K., Boudyguina E.Y., Chung S.K., Smith T.L., et al. Initial interaction of ApoA-I with ATP binding cassette transporter A1 (ABCA1) impacts in vivo metabolic fate of nascent HDL. J Lipid Res 2008, 49:2390-2401.
57. Parks J.S., Rudel L.L. Effect of fish oil on atherosclerosis and lipoprotein metabolism. Atherosclerosis 1990, 84:83-94.
58. Harris W.S. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 1996, 31:243-252.
59. Johnson F.L., Babiak J., Rudel L.L. High density lipoprotein accumulation in perfusates of isolated livers of African green monkeys. Effects of saturated versus polyunsaturated dietary fat. J Lipid Res 1986, 27:537-548.
60. Kralova Lesna I., Suchanek P., Kovar J., Stavek P., Poledne R. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J Lipid Res 2008, 49:2414-2418.
61. Oram J.F., Lawn R.M., Garvin M.R., Wade D.P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000, 275:34508-34511.
62. Soltoff S.P. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 2007, 28:453-458.
63. Wang N., Chen W., Linsel-Nitschke P., Martinez L.O., Agerholm-Larsen B., Silver D.L., et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003, 111:99-107.
64. Martinez L.O., Agerholm-Larsen B., Wang N., Chen W., Tall A.R. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 2003, 278:37368-37374.
65. Demaison L., Moreau D. Dietary n-3 polyunsaturated fatty acids and coronary heart disease-related mortality: a possible mechanism of action. Cell Mol Life Sci 2002, 59:463-477.
66. Schaefer E.J. Effects of dietary fatty acids on lipoproteins and cardiovascular disease risk: summary. Am J Clin Nutr 1997, 65:1655S-1656S.
67. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.